Af­ter un­ex­pect­ed tie, Am­s­ter­dam wins 'coin toss' for new EMA HQ

Well, that was un­ex­pect­ed. The EU’s third and fi­nal vote on the new lo­ca­tion of the Eu­ro­pean Med­i­cine Agency tied be­tween Mi­lan and Am­s­ter­dam, with Am­s­ter­dam win­ning the prover­bial coin toss tie-break­er (EU of­fi­cials drew the city’s name out of a bowl).

The re­sults may sur­prise those fol­low­ing the first two vot­ing rounds close­ly, as Mi­lan came in the lead on the pre­vi­ous ses­sions. Both cities ranked ex­tra­or­di­nar­i­ly well on the EMA’s score­card, with the lo­ca­tions es­pe­cial­ly pop­u­lar with the agency’s 900-per­son staff. The EMA said ear­li­er this month that 65% or more of its staff would be will­ing to re­lo­cate to both Mi­lan and Am­s­ter­dam. Ac­cord­ing to a staff sur­vey in Sep­tem­ber, Am­s­ter­dam would woo the most EMA staffers to re­lo­cate, while Mi­lan ranked fourth.

Staffers like­ly breathed a sigh of re­lief that oth­er top-ranked cities like Bratisla­va and Bucharest did not end up in the top three. Less than 30% of staffers were will­ing to move to those cities, which would have put the EMA in a tough po­si­tion — un­der­staffed and on­ly able to work on top pri­or­i­ty ef­forts.

The EMA has called Lon­don home since 1995, when it was first es­tab­lished. From there, it mon­i­tors and ap­proves drugs across 28 Eu­ro­pean Union mem­ber states and 500 mil­lion peo­ple. Fol­low­ing the Unit­ed King­dom’s vote to ex­it the EU in 2019, the EMA has been scram­bling to choose a site that will meet all of its (many) needs. The re­lo­ca­tion caused a fren­zy of bids from ma­jor cities through­out Eu­rope, first to­tal­ing 19 prospec­tive cities but with three drop­ping out ear­ly this morn­ing: Mal­ta, Za­greb, and Dublin.

The EU’s top cri­te­ria for the EMA’s new home city is ac­ces­si­bil­i­ty to in­ter­na­tion­al trav­el and bilin­gual ed­u­ca­tion for the staffer’s chil­dren. The EMA’s staff has been a ma­jor con­cern, as an ex­o­dus of em­ploy­ees would mean a slow down of process­es. The EMA warned last month that, worst-case sce­nario, its re­lo­ca­tion from Lon­don could per­ma­nent­ly dam­age the med­i­cines reg­u­la­to­ry sys­tem, trig­ger­ing a pub­lic health cri­sis.

If it can’t com­pen­sate for large staff loss­es fol­low­ing its re­lo­ca­tion, it would be forced to in­voke its Brex­it pre­pared­ness busi­ness con­ti­nu­ity plan. The plan has the EMA de­creas­ing its ac­tiv­i­ties to on­ly in­clude those with high pri­or­i­ty. Ac­tiv­i­ties such as cor­po­rate gov­er­nance, au­dits and con­fer­ences are list­ed as the low­est pri­or­i­ties. The top pri­or­i­ties in­clude the as­sess­ment and safe­ty mon­i­tor­ing of med­i­cines and ac­tiv­i­ties vi­tal for main­tain­ing the in­fra­struc­ture of the Eu­ro­pean med­i­cines reg­u­la­to­ry net­work.

To con­tin­ue car­ry­ing out its high­ly pri­or­i­tized ac­tiv­i­ties, the EMA says it needs 462 full time equiv­a­lent (FTE) staff — close to 50% of its cur­rent staff. It needs an­oth­er 140 to car­ry out medi­um pri­or­i­ty work and a fur­ther 110 to con­tin­ue to per­form its low­est pri­or­i­ty ac­tiv­i­ties.

Am­s­ter­dam has a num­ber of things go­ing for it, ac­cord­ing to the EMA’s score­card. It has good flight con­nec­tiv­i­ty to oth­er Eu­ro­pean Eco­nom­ic Area cap­i­tal cities and in­ter­na­tion­al lo­ca­tions. It has ex­cel­lent pub­lic trans­port be­tween the air­port and the pro­posed premis­es of the EMA. It al­so has lots of hous­ing and “high qual­i­ty ac­com­mo­da­tion” with­in walk­ing dis­tance to the pro­posed HQ site. And there’s lots of Eu­ro­pean-ori­ent­ed schools.

Mi­lan had many of the same things go­ing for it, ex­cept the city al­so in­clud­ed de­tails on cur­rent and fu­ture school ca­pac­i­ty for the staffer’s chil­dren, which may have eased wor­ry about putting hun­dreds of new stu­dents in­to lo­cal schools.

Now, the EMA has plen­ty on its plate. The agency has to take up new op­er­a­tions at the Am­s­ter­dam site by March 2019. Fit­ting out the new head­quar­ters alone will take 12-15 months, the agency es­ti­mates. Build­ing one in time will re­quire fast ac­tion and a hur­ry-up con­struc­tion sched­ule.

Re­ac­tions

Here’s Steve Bates, CEO of the UK’s BioIn­dus­try As­so­ci­a­tion:

“Lon­don’s loss is Am­s­ter­dam’s gain. To­day’s de­ci­sion on the lo­ca­tion of the Eu­ro­pean Med­i­cines Agency means a 1000 high qual­i­ty jobs leav­ing the UK, dis­rupt­ing a thou­sand fam­i­lies as a di­rect re­sult of Brex­it, with im­pli­ca­tions for thou­sands more. Busi­ness­es now need cer­tain­ty. The best way to do this is by an ear­ly agree­ment to a tran­si­tion time­frame and con­tin­ued close reg­u­la­to­ry co-op­er­a­tion. We must now en­sure Brex­it does not dis­rupt the safe sup­ply of vi­tal med­i­cines to tens of mil­lions of fam­i­lies in the EU 27 and the UK.”


Mar­tine Dehlinger-Kre­mer, VP of Glob­al Med­ical and Reg­u­la­to­ry Af­fairs at in­ter­na­tion­al CRO Syn­ter­ac­tHCR, says Am­s­ter­dam has all the cri­te­ria to be a suc­cess­ful move:

Am­s­ter­dam is a very dy­nam­ic city and an in­ter­na­tion­al­ly ori­ent­ed city. The Nether­lands of­fers all the fa­cil­i­ties nec­es­sary for the agency to re­lo­cate quick­ly and ef­fi­cient­ly. Am­s­ter­dam will be able to pro­vide good hous­ing, in­ter­na­tion­al schools and health­care for the EMA em­ploy­ees as well as ac­cess to the labour mar­ket for their part­ners. Am­s­ter­dam is well recog­nised med­ical and sci­ence in­dus­try. Am­s­ter­dam has even been nom­i­nat­ed as the Eu­ro­pean Cap­i­tal of In­no­va­tion by the Eu­ro­pean Union. Am­s­ter­dam of­fers one of Eu­rope’s biggest air­ports which will al­low easy and fast ac­cess to the EMA vis­i­tors.”


And Pier­lui­gi Parac­chi, CEO of Italy’s Genen­ta:


Im­age: Am­s­ter­dam Shut­ter­stock

Secretary of health and human services Alex Azar speaking in the Rose Garden at the White House (Photo: AFP)

Trump’s HHS claims ab­solute au­thor­i­ty over the FDA, clear­ing path to a vac­cine EUA

The top career staff at the FDA has vowed not to let politics overrule science when looking at vaccine data this fall. But Alex Azar, who happens to be their boss’s boss, apparently won’t even give them a chance to stand in the way.

In a new memorandum issued Tuesday last week, the HHS chief stripped the FDA and other health agencies under his purview of their rule making ability, asserting all such power “is reserved to the Secretary.” Sheila Kaplan of the New York Times first obtained and reported the details of the September 15 bulletin.

Two wild weeks for Grail end in $8B Il­lu­mi­na buy­out

Grail’s whirlwind two weeks have ended in the wealthy arms of its former founder and benefactors.

Illumina has shelled out $8 billion to reacquire the closely-watched liquid biopsy startup they spun out just 5 years ago and sold off much of its shares just 3 years ago. The deal comes nearly two weeks after the well-heeled startup filed for a potentially massive IPO — one that was disrupted just a week later when Bloomberg reported that Illumina was in talks to buy their former spinout for up to $8 billion.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.

Roche vaults to the front of the NL­RP3 clin­i­cal race, pay­ing $448M up­front to bag In­fla­zome

Roche is going all in on NLRP3.

The pharma giant is putting down $448 million (€380 million) upfront to snatch Novartis-backed Inflazome, which makes it a clinical player in the space overnight.

Dublin and Cambridge, UK-based Inflazome is the second NLRP3-focused biotech Roche has acquired in less than two years, and although no numbers were disclosed in the Jecure buyout, this is almost certainly a much larger deal.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.

As­traZeneca pub­lish­es Covid-19 vac­cine PhI­II pro­to­cols in lock­step with Mod­er­na and Pfiz­er. How are they dif­fer­ent?

Following in the steps of Moderna and Pfizer, the other two American drugmakers currently in Phase III trials for their Covid-19 vaccines, AstraZeneca posted its own study protocols over the weekend. The move is the latest in a series of rare peeks behind the curtain, as such blueprints are typically shared once such trials are completed.

“Given the unprecedented global impact of the Coronavirus pandemic and the need for public information, AstraZeneca has published the detailed protocol and design of our AZD1222 clinical trial. As with most clinical development, protocols are not typically shared publicly due to the importance of maintaining confidentiality and integrity of trials. AstraZeneca continues to work with industry peers to ensure a consistent approach to sharing timely clinical trial information,” the company said in a statement.

Sebastian Nijman (file photo)

Roche looks to ge­net­ic mod­i­fiers for new drug tar­gets, team­ing up with Dutch biotech in $375M deal

Roche is gambling on a new way of discovering drug targets and, ultimately, promising to infuse more than $375 million into a small biotech if all goes well.

A spinout of the Netherlands Cancer Institute and Oxford University, Scenic Biotech set out to pioneer a field that’s gaining some traction among top VCs in the US: to harness the natural protecting powers of genetic modifiers — specific genes that suppress a disease phenotype.

Donald Trump and White House chief of staff Mark Meadows, before boarding Marine One (Getty Images)

Pric­ing deal col­laps­es over Big Phar­ma's re­fusal to is­sue $100 'cash card­s' be­fore the elec­tion — re­port

Late in August, as negotiations on a pricing deal with President Trump reached a boiling point, PhRMA president Stephen Ubl sent an email update to the 34 biopharma chiefs that sit on his board. He wrote that if the industry did not agree to pay for a $100 “cash card” sent to seniors before November, White House chief of staff Mark Meadows was going to tell the news media Big Pharma was refusing to “share the savings” with the elderly — and that all of the blame for failed drug pricing negotiations would lie squarely on the industry.

#ES­MO20: As­traZeneca aims to spur PRO­found shift in prostate can­cer treat­ment with Lyn­parza OS da­ta

AstraZeneca has unveiled the final, mature overall survival data that cemented Lynparza’s first approval in prostate cancer approval — touting its lead against rivals with the only PARP inhibitor to have demonstrated such benefit.

But getting the Merck-partnered drug to the right patients remains a challenge, something the companies are hoping to change with the new data cut.

The OS numbers on the subgroup with BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer are similar to the first look on offer when the FDA expanded the label in May: Lynparza reduced the risk of death by 31% versus Xtandi and Zytiga. Patients on Lynparza lived a median of 19.1 months, compared to 14.7 months for the anti-androgen therapies (p = 0.0175).

Eli Lilly CSO Dan Skovronsky (file photo)

UP­DAT­ED: #ES­MO20: Eli Lil­ly shows off the da­ta for its Verzenio suc­cess. Was it worth $18 bil­lion?

The press release alone, devoid of any number except for the size of the trial, added nearly $20 billion to Eli Lilly’s market cap back in June. Now investors and oncologists will get to see if the data live up to the hype.

On Sunday at ESMO, Eli Lilly announced the full results for its Phase III MonarchE trial of Verzenio, showing that across over 5,000 women who had had HR+, HER2- breast cancer, the drug reduced the odds of recurrence by 25%. That meant 7.8% of the patients on the drug arm saw their cancers return within 2 years, compared with 11.3% on the placebo arm.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.

Greg Friberg (File photo)

#ES­MO20: Am­gen team nails down sol­id ear­ly ev­i­dence of AMG 510’s po­ten­tial for NSCLC, un­lock­ing the door to a wave of KRAS pro­grams

The first time I sat down with Amgen’s Greg Friberg to talk about the pharma giant’s KRAS G12C program for sotorasib (AMG 510) at ASCO a little more than a year ago, there was high excitement about the first glimpse of efficacy from their Phase I study, with 5 of 10 evaluable non-small cell lung cancer patients demonstrating a response to the drug.

After decades of failure targeting KRAS, sotorasib offered the first positive look at a new approach that promised to open a door to a whole new approach by targeting a particular mutation to a big target that had remained “undruggable” for decades.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.